{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:35:35Z","timestamp":1790796935696,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s13311-023-01394-0","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T12:04:20Z","timestamp":1688990660000},"page":"1284-1293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-4776","authenticated-orcid":false,"given":"Giorgio","family":"Lambru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Caponnetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Briscoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna P.","family":"Andreou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1007\/s13311-023-01394-0_bib1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","article-title":"Global prevalence of chronic migraine: a systematic review","volume":"30","author":"Natoli","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-023-01394-0_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s10194-016-0603-3","article-title":"Impact of depression and anxiety on burden and management of episodic and chronic headaches - a cross-sectional multicentre study in eight Austrian headache centres","volume":"17","author":"Zebenholzer","year":"2016","journal-title":"J Headache Pain"},{"issue":"5","key":"10.1007\/s13311-023-01394-0_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-023-01394-0_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-019-0993-0","article-title":"A narrative review on the burden of migraine: when the burden is the impact on people's life","volume":"20","author":"Leonardi","year":"2019","journal-title":"J Headache Pain"},{"issue":"4","key":"10.1007\/s13311-023-01394-0_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14728214.2018.1552939","article-title":"Emerging drugs for migraine treatment: an update","volume":"23","author":"Lambru","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"10.1007\/s13311-023-01394-0_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine","volume":"21","author":"Lambru","year":"2020","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1007\/s13311-023-01394-0_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1007\/s13311-023-01394-0_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s10194-022-01507-8","article-title":"Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis","volume":"23","author":"Andreou","year":"2022","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1007\/s13311-023-01394-0_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","article-title":"Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study","volume":"23","author":"Cullum","year":"2022","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1007\/s13311-023-01394-0_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","article-title":"European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA)","volume":"21","author":"Sacco","year":"2020","journal-title":"J Headache Pain"},{"issue":"4\u20135","key":"10.1007\/s13311-023-01394-0_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/03331024211048765","article-title":"Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study","volume":"42","author":"Overeem","year":"2022","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1007\/s13311-023-01394-0_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1007\/s13311-023-01394-0_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/2193-1801-2-222","article-title":"Principled missing data methods for researchers","volume":"2","author":"Dong","year":"2013","journal-title":"Springerplus"},{"issue":"16","key":"10.1007\/s13311-023-01394-0_bib14","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0333102412462642","article-title":"Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study","volume":"32","author":"Silberstein","year":"2012","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1007\/s13311-023-01394-0_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0333102410381142","article-title":"Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study","volume":"31","author":"Saper","year":"2011","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1007\/s13311-023-01394-0_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s10194-020-01171-w","article-title":"Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region","volume":"21","author":"Ornello","year":"2020","journal-title":"J Headache Pain"},{"key":"10.1007\/s13311-023-01394-0_bib17","author":"National Institute for Health and Care Excellence"},{"key":"10.1007\/s13311-023-01394-0_bib18","author":"National Institute for Health and Care Excellence"},{"issue":"6","key":"10.1007\/s13311-023-01394-0_bib19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1007\/s13311-023-01394-0_bib20","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"issue":"10203","key":"10.1007\/s13311-023-01394-0_bib21","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1007\/s13311-023-01394-0_bib22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","article-title":"Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"21","author":"Ashina","year":"2022","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1007\/s13311-023-01394-0_bib23","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/head.13966","article-title":"Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study","volume":"60","author":"Buse","year":"2020","journal-title":"Headache"},{"issue":"1\u20132","key":"10.1007\/s13311-023-01394-0_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"issue":"3","key":"10.1007\/s13311-023-01394-0_bib25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/bph.15605","article-title":"Beyond CGRP: the calcitonin peptide family as targets for migraine and pain","volume":"179","author":"Rees","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1007\/s13311-023-01394-0_bib26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0333102420977106","article-title":"Interictal amylin levels in chronic migraine patients: a case-control study","volume":"41","author":"Irimia","year":"2021","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1007\/s13311-023-01394-0_bib27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/ana.26072","article-title":"Amylin Analog pramlintide induces migraine-like attacks in patients","volume":"89","author":"Ghanizada","year":"2021","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"10.1007\/s13311-023-01394-0_bib28","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1007\/s10072-012-1060-7","article-title":"Polytherapy for migraine prophylaxis","volume":"33","author":"Casucci","year":"2012","journal-title":"Neurol Sci"},{"key":"10.1007\/s13311-023-01394-0_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.656294","article-title":"Additive interaction between onabotulinumtoxin-A and erenumab in patients with refractory migraine","volume":"12","author":"Silvestro","year":"2021","journal-title":"Front Neurol"},{"issue":"2","key":"10.1007\/s13311-023-01394-0_bib30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","article-title":"Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review","volume":"10","author":"Blumenfeld","year":"2021","journal-title":"Pain Ther"},{"issue":"4","key":"10.1007\/s13311-023-01394-0_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231156922","article-title":"Randomized controlled studies evaluating topiramate, botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: a systematic review and meta-analysis","volume":"43","author":"Giri","year":"2023","journal-title":"Cephalalgia"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01394-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01394-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301927X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301927X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01394-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:12:21Z","timestamp":1761808341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792301927X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S187874792301927X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01394-0","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01394-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}